Citation Impact
Citing Papers
Hyperplasia and Carcinomas in Pten-Deficient Mice and Reduced PTEN Protein in Human Bladder Cancer Patients
2006 StandoutNobel
Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233
2014
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Current knowledge on exosome biogenesis and release
2017 Standout
Upper urinary tract abnormalities in multiple sclerosis patients with urinary symptoms
1996
Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions.
1998
New Technology and Health Care Costs — The Case of Robot-Assisted Surgery
2010 Standout
Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
2010 Standout
Photodynamic Therapy
1998 Standout
The role of porphyrin chemistry in tumor imaging and photodynamic therapy
2010 Standout
Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer
2006
The effect of age and gender on bladder cancer: a critical review of the literature
2009
Prostate cancer detection with magnetic resonance imaging: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging?
2010
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter
2004 Standout
Hydrogels for tissue engineering: scaffold design variables and applications
2003 Standout
The present and future role of photodynamic therapy in cancer treatment
2004 Standout
Bladder cancer in the elderly
2009
Clinical development and potential of photothermal and photodynamic therapies for cancer
2020 Standout
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
2017 Standout
Permutation tests for joinpoint regression with applications to cancer rates
2000 Standout
Screening decreases prostate cancer mortality: 11‐year follow‐up of the 1988 Quebec prospective randomized controlled trial
2004
Population‐based 10‐year oncologic outcomes after low‐dose‐rate brachytherapy for low‐risk and intermediate‐risk prostate cancer
2012
PRECLINICAL EXAMINATION OF FIRST and SECOND GENERATION PHOTOSENSITIZERS USED IN PHOTODYNAMIC THERAPY
1991
Hyaluronan: from extracellular glue to pericellular cue
2004 Standout
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
1998 Standout
Multiplexed electrical detection of cancer markers with nanowire sensor arrays
2005 Standout
Design of the Prostate Cancer Prevention Trial (PCPT)
1995
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Accelerated Radiotherapy, Carbogen, and Nicotinamide (ARCON) in the Treatment of Advanced Bladder Cancer: Mature Results of a Phase II Nonrandomized Study
2008
Revisiting photodynamic therapy dosimetry: reductionist & surrogate approaches to facilitate clinical success
2016
Prostate cancer
2015
Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience
2011
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Exosomes as Biomarker Enriched Microvesicles: Characterization of Exosomal Proteins Derived from a Panel of Prostate Cell Lines with Distinct AR Phenotypes
2012
URODYNAMICS AND MULTIPLE SCLEROSIS
1996
Bladder Preservation Strategies
2014
Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination
1993
Clinical exercise interventions in prostate cancer patients—a systematic review of randomized controlled trials
2011
The Influence of Finasteride on the Development of Prostate Cancer
2003 Standout
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
2015 Standout
A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation Therapy
2013
Preoperative 3-Tesla Multiparametric Endorectal Magnetic Resonance Imaging Findings and the Odds of Upgrading and Upstaging at Radical Prostatectomy in Men With Clinically Localized Prostate Cancer
2012
Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review
2014
EAU Guidelines on Prostate Cancer
2007 Standout
Bladder cancer
2016 Standout
Cancer treatment and survivorship statistics, 2012
2012 Standout
Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid–hyaluronidase and BTA‐Stat tests
2002
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Injectable agents in the treatment of stress urinary incontinence in women: where are we now?
2000
Photodynamic therapy of cancer: An update
2011 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence declinein the United States
1998
Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer.
1993
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2
2015 Standout
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial
2013
Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?
2006
Interstitial photodynamic therapy for prostate cancer: a developing modality
2004
In vivo imaging of tumors with protease-activated near-infrared fluorescent probes
1999 Standout
Evaluating the role of photodynamic therapy in the management of pancreatic cancer
1995
Mitochondria and cancer
2012 Standout
Prostate-specific antigen
2000
Radiomics: the bridge between medical imaging and personalized medicine
2017 Standout
A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma
2008
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
2014 Standout
Outcome of sextant biopsy according to gland volume
1997
Analytical performance of the Roche total and free PSA assays on the Elecsys 2010 immunoanalyzer
2002
Light dosimetryin vivo
1997
Prostatic Specific Antigen
1994
Global cancer statistics in the year 2000
2001 Standout
EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013
2013 Standout
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
2003 Standout
Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and Therapy
2011
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
2012 Standout
Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06
2009
Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610
2008
Androgen Deprivation Therapy and Future Alzheimer’s Disease Risk
2015
A Phase II Clinical Trial of Neoadjuvant Ketoconazole and Docetaxel Chemotherapy Before Radical Prostatectomy in High Risk Patients
2011
Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Before Radical Prostatectomy for Patients With High Risk Localized Prostate Cancer
2008
Bladder Cancer
2020 Standout
The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer
2002 StandoutNobel
Electrochemiluminescence (ECL)
2004 Standout
Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer
2008
The diagnosis, management, treatment and costs of prostate cancer in England and Wales.
1997
Gold Nanoparticles in Chemical and Biological Sensing
2012 Standout
High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study.
2013
Cancer treatment and survivorship statistics, 2016
2016 Standout
Cancer statistics, 2016
2016 Standout
Cancer statistics, 2015
2015 Standout
Cancer treatment and survivorship statistics, 2019
2019 Standout
The phosphatidylinositol‐3 kinase pathway regulates bladder cancer cell invasion
2003
Chemistry of Biologically Important Synthetic Organoselenium Compounds
2001 Standout
Angiogenesis in urological malignancy: prognostic indicator and therapeutic target
1999
The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation
2013
Screening for Prostate Cancer With the Prostate-Specific Antigen Test
2014
Mechanisms of Pulsed Laser Ablation of Biological Tissues
2003 Standout
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Organ Conservation in Invasive Bladder Cancer by Transurethral Resection, Chemotherapy and Radiation: Results of a Urodynamic and Quality of Life Study on Long-term Survivors
2003
Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
2009
Preventives Versus Treatments *
2015 StandoutNobel
Do Fixed Patent Terms Distort Innovation?: Evidence from Cancer Clinical Trials
2013
Prostate Cancer Screening in the Midst of Controversy: Canadian Men’s Knowledge, Beliefs, Utilization, and Future Intentions
1997
Enzyme-Amplified Array Sensing of Proteins in Solution and in Biofluids
2010
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of Michael Chetner being referenced
Optical dosimetry for interstitial photodynamic therapy
1989
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
2011
Muscle-invasive transitional cell carcinoma of the urinary bladder: a population-based study of patterns of care and prognostic factors
2001
CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results
1999
Return to Continence After Radical Retropubic Prostatectomy: A Randomized Trial of Verbal and Written Instructions Versus Therapist-Directed Pelvic Floor Muscle Therapy
2008
Periurethral implantation of glutaraldehyde cross‐linked collagen (contigen®) in women with type I or III stress incontinence: quantitative outcome measures
1995
Prostate cancer screening: Canadian guidelines 2011
2011
Lower urinary tract dysfunction in multiple sclerosis
1992
Diagnosis of Prostatic Carcinoma: The Yield of Serum Prostate Specific Antigen, Digital Rectal Examination and Transrectal Ultrasonography
1994
The Initial Results in Muscle-Invading Bladder Cancer of RTOG 95-06: Phase I/II Trial of Transurethral Surgery Plus Radiation Therapy with Concurrent Cisplatin and 5-Fluorouracil Followed by Selective Bladder Preservation or Cystectomy Depending on the Initial Response
2000
Associations Among Age, Comorbidity and Clinical Outcomes After Radical Cystectomy: Results From the Alberta Urology Institute Radical Cystectomy Database
2008
RANDOMIZED COMPARATIVE STUDY OF 3 VERSUS 8-MONTH NEOADJUVANT HORMONAL THERAPY BEFORE RADICAL PROSTATECTOMY: BIOCHEMICAL AND PATHOLOGICAL EFFECTS
2001
Screening for Prostatic Carcinoma with Prostate Specific Antigen
1992
GUIDELINES FOR THE SURVEILLANCE OF LOCALIZED RENAL CELL CARCINOMA BASED ON THE PATTERNS OF RELAPSE AFTER NEPHRECTOMY
2004